The Mef2 family transcriptional regulator Mef2c (myocyte enhancer factor 2c) is highly expressed in maturing bone marrow and peripheral mature B-cells. To evaluate the role of this transcription factor in B-cell development, we generated a B-cell-specific conditional deletion of Mef2c using the Mb-1-Cre transgene that is expressed during the early stages of immunoglobulin rearrangement. 
Introduction
B-cell lineage commitment, development and the response to antigen binding are all steps of B-cell function that are tightly controlled by a highly intertwined network of transcription factor guided gene expression (1) . Initial development of B-cells starts in the bone marrow with the common lymphoid progenitor cell giving rise to the Pro-B-, Pre-B-and immature B-cell stages. Signals from CD79a (Mb1), CD19, CD45 and pre-BCR or mature BCR on the surface of these cells are required for appropriate maturation in the bone marrow. Transcription factor signaling networks controlled by E2A, EBF, Pax5, IRF4/8 and other factors help govern this pathway (1) . Surface IgM expressing immature B-cells (B220 + CD19 + ) exit the bone marrow and populate peripheral B-cell developmental sites, such as the spleen, as transitional type cells (T1 or T2), which further differentiate into mature follicular (FM) or marginal zone (MZ) B-cell subsets. A variety of transcription regulatory factors including NF-κB, Notch2, OBF1 and others are implicated in the splenic maturation of FM and MZ B-cells (1) . The Mef2 (myocyte enhancer factor 2) family of transcription factors was originally described in muscle development (2) (3) (4) . There are four members of the Mef2 family present in mice: Mef2a, Mef2b, Mef2c and Mef2d. All of these proteins share a highly homologous MADS domain and MEF2 motif for DNA binding, homo/hetero dimerization and cofactor interactions. Transcriptional activators such as p300/PCAF, NFAT, GATA, ERK5 and transcriptional repressors such as HDAC4/5/7/9 and MITR are known to interact with MEF2 family members in order to regulate target gene expression (5, 6) . Mef2 family members are critical in controlling responses to calcium signaling and p38 MAPK pathway (7, 8) . In total, the Mef2 proteins influence a wide array of cellular pathways including skeletal muscle development, cardiac morphogenesis, bone development, neural crest development, vascular integrity, neuronal differentiation and hematopoietic system development including the myeloid versus lymphoid decision.
The expression of Mef2c is evident in the early stages of marrow B-cell development and is elevated with B-cell maturity (9) . Since the total absence of Mef2c is lethal, conditional knockout models have been used to examine the role of Mef2c in early murine lymphoid development and downstream of BCR signaling in mature splenic B-cells (10) (11) (12) . When Mef2c is deleted early in hematopoietic development (using an interferon-inducible Mxl-Cre transgene) the lymphoid lineages are lost (including the common lymphoid progenitor cell) coupled with enhanced myeloid lineage production (11) . Another study analyzed the loss of Mef2c using a Vav-Cre construct that deletes the gene shortly after the development of the hematopoietic stem cells (HSCs). Such mice displayed normal numbers of mature cell lineages (with the exception of platelets) and a depressed level of bone marrow B-cell homeostasis with a specific depression in the production of Hardy fraction A pre-pro-B-cells (13) . These two reports thus demonstrate that Mef2c is required at two distinct checkpoints of B-cell development, the choice between lymphoid and myeloid lineages, and the generation of the pre-pro B-cell subclass. Wilker et al. and Khiem et al. utilized Cd19-Credependent approaches to define the function of Mef2c in mature B-cells (10, 12) . These reports demonstrated a role of Mef2c in mature B-cell proliferation and survival after BCR stimulation, linking survival to the p38 MAPK pathway. No defect in B-cell development was noted in these studies using the Cd19-Cre deleter strain to inactivate the Mef2c gene.
Our previous analysis of Mef2c expression in maturing and mature B-cells demonstrated that the gene was transcriptionally active in the earliest B220 + B-cell subsets of the marrow with enhanced expression in the most mature B-cell populations (9) . The expression of Mef2c was highest in FM B-cells as compared with MZ B-cells. We chose to analyze the role of Mef2c in the maturation of marrow B-cells to their mature peripheral counterparts using a Mb-1-Cre (Cd79a) deleter strain (14) . Mb-1 is strongly expressed from the very early pro-B-cell stage in the marrow to the final differentiation of the B-cell into a plasma cell, thus its induction of expression is after Vav but before Cd19. The Mb-1-Cre animal has also been shown to be highly efficient in the deletion of flox'd genes in bone marrow B-cells (14-16) allowing us to assess the impact of deleting Mef2c in the early stages of B-cell development.
In this study, we utilized the Mb-1-Cre-mediated deletion model of Mef2c to evaluate the role of this protein during B-cell development and differentiation in the bone marrow and spleen. The development of marrow and splenic B-cells in young mice was significantly impaired in the absence of Mef2c; however, mature animals regained normal numbers and subtypes of mature peripheral B-cells. The expression of FcɛR2α (CD23) was impaired in a specific subset of maturing and mature B-cells. Interestingly the production of several key B-cell functional/regulatory proteins including Ciita, Cr2 and Tnfsf4 (Ox40l) was also altered. The direct role of Mef2c in regulating the expression of several of these genes was demonstrated by chromatin immunoprecipitation (ChIP) of the Mef2c protein on the promoters of these genes.
Methods

Mice and animal care
Mef2c
fl/fl (17) 
Genomic DNA isolation and genotyping
To isolate genomic DNA from tail-biopsies, 5-mm sections of mouse tails were boiled in 50 mM NaOH for 90 min followed by neutralization with 1 M Tris. Insoluble debris was removed by centrifugation and DNA was pelleted following ethanol precipitation at −20°C. DNA was resuspended in nanopure sterilized water. Genomic DNA was prepared from spleen or bone marrow cells by lysing the cells in RIPA (50 mM NaCl, 25 mM Tris: pH7.5, 1 mM EDTA, 0.1% SDS, 1% w/v deoxycholate, 1% Noniodet P-40) with the addition of Proteinase K solution at 62°C for an hour. Organic debris was removed by phenol/chloroform and chloroform extraction and DNA precipitated with ethanol.
Mef2c genotyping was performed as described by Arnold et al. (17) and the oligonucleotides utilized described in Fig. 1 
Magnetic cell separation and flow cytometry
Single cell suspensions from the spleen or bone marrow were isolated as previously described (18) . B-cell purification was performed using B220 + magnetic beads according to the manufacturer's protocol (Miltenyi Biotech, CA, USA). Staining of cells for FACS analysis was performed as described (14) . The following antibodies were used for cell staining: CD23 (B3B4), CD24 (M1/69), CD93 (AA4.1), CD43 (eBioR2/60), and CD45.2 (104) from eBioscience (San Diego, CA, USA), CD21 (7G6), CD35 (8C12) and MHC class II I-A/I-E (2G9) from BD Pharmingen (San Jose, CA, USA) and B220 (RA3-6B2) and CD45.1 (A20) from BioLegend (San Diego, CA, USA). The FACSCalibur and FACSCanto (BD Biosciences, San Diego, CA, USA) machines were used to detect labeled cells and CellQuest (BD Biosciences) was used for analysis of cell populations. 
Quantitative RT-PCR and microarray analysis
For quantitative RT-PCR, total cellular RNA was isolated using Illustra RNA Spin Mini Kit (GE Healthcare, UK) according to the manufacturer's protocol. Freshly isolated RNA was used to synthesize cDNA by mixing 10 μl of 5× first strand synthesis buffer, 5 μl of 5 mM dNTP, 5 μl of 0.1 M DTT, 1 μl of 1.25 mM random primers and 2 μl of Maloney murine leukemia virusreverse transcriptase (Invitrogen, CA) and water to a final volume of 50 μl. The final reaction mix was incubated at 37°C for 2 h followed by an additional 5-min incubation with 2 μl DNAse free RNAse (Invitrogen). cDNA was purified using the Genejet PCR Purification kit (Fermentas, MD) as per the manufacturer's instructions. Quantitative real-time RT-PCR was performed using the Light Cycler (Roche Diagnostics, IN) as described previously (19 For microarray analysis, B220 + cells were isolated from 2-week bone marrow and 8-week spleen populations using magnetic beads. The Illustra RNA kit was again used to isolate total RNA from B220 + cells. RNA from multiple animals was then pooled to generate each sample. RNA samples were then labeled, hybridized to the Whole Mouse Genome Microarray (Agilent, CA) and scanned by the Microarray Core Facility at the University of Utah. Microarray results were analyzed using Genesifter (Geospiza, WA) with assistance from the Bioinformatics Core Facility at the University of Utah. Agilent data tables that were generated in these assays have been deposited with the Geo data base and are available at http://www.ncbi.nlm.nih.gov/geo/query/acc. cgi?acc=GSE34210 (Geo database, study GSE34210).
ChIP assay
ChIP was performed as previously described (20) and is summarized below. The B-cell line, Wehi-231, was utilized (3 × 10 6 cells/ChIP). Cells were resuspended in 1% formaldehyde and DNA/protein complexes cross-linked by room temperature incubation for 15 min. Cross-linking reactions were halted by the addition of 2.5 M glycine and cells were lysed in radio-immunoprecipiation buffer. After lysis, samples were sonicated at a power setting of 4 for a 1-h duration using 30 s on/off cycles. Debris was pelleted at 4°C at 13 200 r.p.m. for 15 min and supernatants were transferred to new 1.5-ml tubes.
Samples were precleared for 2 h at 4°C with previously blocked Protein G Dynabeads. For each immunoprecipitation reaction, 3 μg of an αMef2c mouse monoclonal antibody (Santa Cruz Biotechnology, Inc. Santa Cruz, CA USA; sc-365862) or isotype control was used. In addition, select samples were also immunoprecipitated with 1 μg of an αMef2c goat polyclonal antibody (Santa Cruz; sc-13268) or isotype control. Immune complexes were formed overnight at 4°C. The following day, immunoprecipitations were incubated with Protein G Dynabeads for 2 h at 4°C. Samples were then washed as previously described (excluding the use of herring sperm DNA). Cross-links were reversed by incubation in ChIP elution buffer at 65°C overnight and DNA was isolated using the Fermentas GeneJET purification kit. PCR 
In vitro B-cell culture system
The OP9-DL1 stromal cell line was maintained at 37°C/5% CO 2 in high glucose DMEM media (Invitrogen) with 20% bovine growth serum (HyClone, UT) and 1% penicillin-streptomycin (Invitrogen). On day '0', total splenocytes from mature C57BL/6 or Mef2c conditional knockout (KO) Mef2c
mice were plated onto the OP9-DL1 cells at a density of 5 × 10 6 cells/well of 6-well plate in 2 ml of RPMI media (with 10% bovine growth serum and 1% penicillin-streptomycin). A single dose of recombinant BAFF (Peprotech, NJ) at a final concentration of 0.5 μg/ml was added in each individual well. Splenocytes were harvested 72 h post-treatment and analyzed by FACS analysis.
Bone marrow competition assay
B6-Ly5.2 mice were lethally irradiated with 1050 cGy, split into two doses of 525 cGy with 2 h between doses. Mice were then housed overnight and given antibiotic water. The next day, bone marrow from sex-matched B6-Ly5.2 and Mef2c KO animals was isolated and combined at a 1:1 ratio. Irradiated mice were reconstituted with 2 × 10 6 cells via retro-orbital injection. At 4 and 11 weeks after reconstitution, peripheral blood lymphocytes were obtained from the tail vein and stained for FACS analysis.
OT-II TCR transgenic T-cell proliferation assays
The OT-II TCR transgenic line (21) is specific for the ovalbumin (OVA) peptide 323-339 (Ile-Ser-Gln-Ala-Val-His-Ala-AlaHis-Ala-Glu-Ile-Asn-Glu-Ala-Gly-Arg). B220 RNA from mature C57BL/6 and Mef2c KO mice was isolated from total or B220 + spleen and bone marrow cell populations. Quantitative PCR was performed using primers 4531/4532. Mef2c transcript levels were normalized to β-actin. Data represent the average of three independent experiments (mean ± SD, **P ≤ 0.01, ***P ≤ 0.001).
positive magnetic sorting. Cells were split into aliquots and incubated with 1, 10 and 100 μM concentrations of the peptide (American Peptide Co, Sunnyvale, CA) for 45 min at 37°C with shaking as described (22) . The peptide-pulsed B-cells were then washed three times in RPMI and incubated with carboxyfluorescein succinimidyl ester (CFSE)-loaded total splenocytes (a 1:1 ratio of 4 × 10 5 B-cells and 4 × 10 5 OT-II splenocytes per 96-plate well) from the OT-II animal in the absence of any additional peptide. After 4 days, cells were isolated and analyzed by FACS for CFSE staining within the CD4 + T cells population. B-cell cultures without exogenous peptide were used as negative control and displayed no proliferation (see below).
Statistical analysis
Data are presented as mean values ± standard deviation. Statistical significance was determined with the Student's t-test.
Results
Generation of B-cell specific Mef2c deletion model using Mb-1-Cre
Mice with an early B-cell-specific Mef2c deletion ( 
B-cell development is delayed in maturing Mef2c KO animals
A mouse spleen does not possess fully developed B-cell compartments until about 4-6 weeks after birth; B-cells in immature spleens are primarily of the transitional phenotype (9, 23). We analyzed bone marrow and spleens from 2-week-old animals for B-cell populations and numbers. As shown in Fig. 2 , 2-week Mef2c KO animals (Immature) possessed significantly fewer B220 + B-cells in these two compartments than the same age control animal (C57BL/6). This deficiency was not due to the presence of the Mb-1-Cre allele (as a heterozygote) in that repeated analysis of mice possessing heterogeneity in the Mb-1 gene (Mef2c
) demonstrated equivalent B-cell numbers and types in 2-week bone marrow and spleen as compared with the control animals ( Supplementary Fig. 1 , available at International Immunology Online) and as previously described (14) . Fig. 2 , available at International Immunology Online).
The previous analysis of the Mx1-Cre animals (using a bone marrow chimera model) demonstrated the absence of lymphocytes from the Mef2c-deficient marrow lineages thus we wished to determine whether the same effect was observed with the Mb-1-Cre Mef2c KO model. We found that the reconstitution of blood B-cells from either the WT or Mef2c KO animal was equally efficient (as were cell types of all bone marrow lineages) and thus the absence of Mef2c in those cells did not block their differentiation or maturation ( Supplementary Fig. 3 , available at International Immunology Online).
Previously we described an in vitro tissue culture condition that allows for the derivation of B-cells with FM and MZ phenotypes by co-culturing marrow or splenic B-cell populations on OP9 stromal cells expressing the DL1 notch ligand in the presence of excess B-cell activating factor (BAFF) (24) . We used this culture system to analyze B-cell populations in immature bone marrow (2 weeks of age). Total marrow populations were analyzed to broadly assess CD23 expression on all possible B-cell populations. As shown in Fig. 3A , the freshly isolated marrow from the Mef2c KO animal demonstrates depressed levels of total immature B-cells (B220 
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analyzed by flow cytometry (Fig. 3B) . The differences in phenotypes between the C57BL/6 and Mef2c KO marrow cells are largely lost with the cultured cells suggesting that the addition of exogenous BAFF (immature B-cells of the marrow do express the BAFF receptor) (25) 106 Mef2c conditional loss in mouse B-cells in this section indicate that the absence of Mef2c in the marrow depresses the development of B lineage cells but that, in the peripheral tissues of the mature animal, B-cell numbers and populations reach WT levels, potentially due to the effect of exogenous cytokines such as BAFF.
Mef2c deficient animals demonstrate altered expression of B-cell Fc εR2α/CD23
Recent reports using the CD19-Cre-deleter mediated B-cellspecific Mef2c deletion have shown significant effects on CD23 surface expression (10, 12) . CD23, the low-affinity IgE receptor, is widely used as a B-cell surface molecule to distinguish between mature B-cell subsets (26, 27) 
To clarify these data, we analyzed the expression of CD23 using the Mb-1-Cre driven Mef2c KO model system.
As shown in Fig. 4A , significant reduction in frequency of CD23-expressing B220 + cells in the 2-week (immature) and 8-week (mature) spleen of the Mef2c KO animal was noted as compared with that of the control, C57BL/6. The numbers of B-cells are the same between the Mef2c KO and WT 8-week spleen (about 55% and 53%, respectively); however, the CD23 negative fraction of these cells is significantly increased in the Mef2c KO animals. The mean fluorescent intensity of CD23 staining on the strongly CD23 + cells in both samples is virtually identical (data not shown) indicating that for a subset of splenic B-cells, CD23 expression is unaffected by the loss of Mef2c. Quantitative RT-PCR analysis demonstrated that the loss of CD23 on the B-cell surface of Mef2c KO B-cells coincided with the loss of CD23 transcripts in such cells (Fig. 4B) . The expression of CD23 protein on the surface of cells has been shown to be influenced by the expression/activity of the ADAM10 protease (28, 29) . No change in expression of ADAM10 in such cells was observed (data not shown). Additionally, to determine whether the down-regulation of CD23 surface expression shifted FM/MZ ratios in the mature spleen, IgM and IgD staining of the B220 + cells from WT and the Mef2c KO animals was performed: there was no change in the staining for these surface Ig proteins between the WT and Mef2c KO sample (data not shown). There was also no alteration in CD23 expression in the Mef2c
+/cre animals (data not shown). In total these results indicate that the loss of expression of CD23 in the Mef2c KO cells is due to insufficient CD23 transcript, and that the partial phenotypic loss of CD23 on the cell surface most closely matches our data.
We further extended the analysis of CD23 expression in mature splenic B-cells by sorting B220 + B-cells from C57BL/6 and Mef2cKO animals, gating based upon CD23 expression, and analyzing populations based upon CD21 and CD24 expression. As shown in 
Differential gene expression analysis of Mef2c-deficient bone marrow and spleen B-cells
The depressed numbers of maturing B-cells in immature bone marrow and spleen, the previously reported inhibition of B-cell development and activation in animals lacking the Mef2c protein (10, 12, 13) and the altered expression of CD23 suggests that a number of distinct pathways are regulated by Mef2c. To try to elucidate such pathways, we isolated B220 + B-cells from 2-week BM and 8-week spleen from C57BL/6 and Mef2c KO animals, and performed gene grid array analysis using the whole mouse platform from Agilent (Geo database, study GSE34210). Total B220 + B-cells were analyzed in these arrays since Mef2c is expressed in immature B220 + marrow B-cells, T1, T2, FM and MZ splenic B-cells (9) . Many genes showed altered expression in these assays. A subset of such genes whose altered expression is known to influence B-cell development and function (such as Ciita) and others implicated in such responses (such as Klf12) are shown in Table 1 . Ciita transcript levels were depressed in the Mef2c KO animal in both marrow (4.1-fold) and mature spleen (23.8-fold) samples. Since Ciita is a master regulator of MHC class II gene expression, it was not surprising to note depressed levels of H2-Ab1 and H2-Eb1 in the samples. As noted above, the expression of Fc er2a was also depressed. Hdac9 has been reported to be dependent on Mef2c for optimal expression (30) . Comparison of expression levels of these select genes from a previous screen of Ciita deficient splenic B-cells (9) is included within this table. Also included within the table are the values obtained from a similar analysis using the Cd19-Cre animal for the deletion of Mef2c (12) . This analysis did not show the same range of altered gene expression as did ours perhaps due to the differential timing of expression of the Mef2c is not only a transcriptional activator but is also implicated as serving to down-regulate gene expression, especially in complexes with other chromatin modifiers (30, 31) . A subset of genes demonstrating enhanced expression in the absence of Mef2c is also shown in Table 1 . Of these Ctse (encoding cathepsin E) is notable in that this gene has previously been described as being negatively regulated by Ciita (32) . Tnfsf4 (Ox40l) is a potent co-stimulatory protein for the optimal activation of CD4 T cells (33) . Its expression is elevated in the Mef2c KO samples suggesting its expression may be directly suppressed by the presence of Mef2c. Cr2, the gene encoding the Cr1 and Cr2 protein, also displayed enhanced expression in the absence of Mef2c.
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To confirm the altered expression profiles noted in Table 1 , flow cytometry and quantitative RT-PCR analyses were carried out on WT and Mef2c KO splenic B-cells. As shown in Fig. 7A , the expression of the H2-Aβ is depressed, but not lost, from the surface of mature B-cells, indicative of the relative loss of Ciita in such cells. Using antibodies that can recognize Cr1/Cr2, and Cr1 alone, the expression of these proteins was shown to be elevated on the surface of the splenic B-cells lacking Mef2c. Quantitative transcript analysis demonstrated that mRNA specific for Cr1, Cr2, and common for both products (Cr1/Cr2) were elevated in B220 + splenic B-cells (Fig. 7B) confirming the gene grid array data. Similarly the expression of Ciita is reduced in the marrow and splenic sample (B220 + -enriched cells) while the expression of Tnfsf4 is elevated in such samples, confirming the gene grid array analysis. Thus Mef2c can act, in B-cells, as either a transactivator or repressor depending upon the specific gene target, similar to its mode of action in skeletal muscle cells.
Fcer2a, Cr2 and Ciita genes are direct target genes of Mef2c transcription factor
The altered expression of the Cr2, Fcer2a/CD23 and Ciita genes in the absence of Mef2c suggests these genes may be direct targets for Mef2c binding. Alternatively the altered expression of the H2-Ab and Ctse genes is likely indirect and due to the depressed expression of Ciita. The Cr2, Fcer2a and Ciita gene promoters do possess canonical Mef2c-binding sites. The Hdac9 gene has been previously described as a direct target of Mef2c binding and transcriptional regulation (30) . To determine whether Mef2c can bind directly to these gene promoters in B-cells, we utilized ChIP analysis using the B-cell Wehi 231 cell line and an antiMef2c monoclonal antibody. The B-cell WeHi 231 cell line is a IgM + cell line, possesses the Mef2c protein and expresses many genes encoding mature B-cell products (34 and data not shown). Along with the Cr2, Fcer2a (proximal) and Ciita gene promoter sequences, we also analyzed Mef2c binding to a sequence 2 kb 5′ of the CD23/FcɛR2α promoter (Distal) and the Hdac9 promoter region. As shown in Fig. 8 , Mef2c demonstrated specific binding to the Cr2, Fcer2a, Ciita and Hdac9 gene promoters. Little detectable binding was evident at the Fcer2a distal site. These data suggest that in the normal B-cells, Mef2c directly regulates, in both positive and negative mechanisms, the expression of the Cr2, Fcer2a, Ciita, and Hdac9 genes.
Analysis of genes showing altered expression in Mef2c KO B-cells during development and function
The decreased expression of Ciita and subsequent depressed expression of MHC class II genes suggested that one immune defect associated with the loss of Mef2c would be depressed antigen presentation via the MHC class II proteins. To test for this effect B220 + B-cells were isolated from the Mef2c KO and WT animals, and pulsed with an OVAspecific peptide (see Methods section). After washing, the peptide-pulsed B-cells were incubated with CFSE-labeled OT-II T cells that specifically recognize this peptide in context of MHC II (22) . We had expected to observe depressed T-cell proliferation with the Mef2c-deficient B-cells, as compared with WT, due to the depressed presentation of the OVA peptide but instead we saw the opposite, that the absence of Mef2c actually promoted T-cell proliferation (Fig. 9) . As shown in Fig. 9A , peptide stimulation (10 μm) with the Mef2c (12) . Agilent data tables that were generated in these assays have been deposited with the Geo data base and are available at http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE34210 (Geo database, study GSE34210). Fig. 5 , available at International Immunology Online). These results were opposite to the prediction and suggested that the absence of Mef2c allowed for the enhanced production of a molecule that could stimulate T-cell proliferation and apparently override the depressed antigen-presentation potential. The expression of the Tnfsf4 gene (Ox40l) is elevated in the Mef2c-deficient B-cells (Table 1) and ligation of the receptor (Tnfrsf4/Ox40) for this ligand on CD4 + cells is known to enhance their survival and proliferation (35, 36) . Therefore the enhanced expression of the Tnfsf4 protein on the surface of the Mef2c KO B-cells may override the anticipated compromised antigen presentation pathway. We also analyzed the Mef2c KO mice for their ability to respond to antigen using the T-cell-dependent antigen TNP-KLH. As shown in Supplementary Fig. 6 (available at International Immunology Online), the Mef2c KO animal demonstrated depressed antigen-specific responses as compared with WT, which is comparable to previous results (12) . Thus the loss of Mef2c has the potential to alter many distinct signaling and activation pathways of mature B-cells (10, 12) .
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The Mef2c KO grid array was also analyzed for genes encoding transcriptional control proteins whose expression could influence the maturation of marrow B-cells. As shown in Table 2 , these genes fell into two categories: the first Confirmation of altered expression of several of the genes shown in Tables 1 and 2 whose over-or under-expression could alter B-cell maturation, is shown in Supplementary  Fig. 6C (available at International Immunology Online). Srpk3 expression is depressed in both marrow and spleen samples from the Mef2c KO animal while Bst1 and Camp (the gene encoding cathelicidin antimicrobial peptide) show increased expression in the Mef2c KO samples. Interestingly although altered expression of Camp was first detected in the B220 + B-cell grid array analysis (see Table 1 ) the total spleen shows a much greater change in expression of the gene than just the B-cell samples. These data indicate that the absence of Mef2c in B-cells induces the elevated expression of Camp in splenic cell types other than B-cells, presumably by the elevated release of a trans-acting factor. Previously induction of Camp expression has been linked to exogenous addition of vitamin D3 (38, 39) . Our data suggest that Mef2c in B-cells suppresses the expression of a factor that can act in an analogous fashion to induce Camp expression by resident myeloid cells of the spleen and marrow. Bst1 is a glycosyl-phosphatidylinositol-anchored protein expressed by stromal cells and transiently by T and B-cells during antigen receptor rearrangement stages (40) , which is the stage of B-cell development we see altered in the Mef2c KO animals. Bst-1 signals through focal adhesion kinase (41) , which serves to regulate cell survival, migration and proliferation (42) , thus the elevated expression of Bst1 by the Mef2c KO B-cells (as compared with WT) may directly influence the kinetics of their development. 
Discussion
The goal of this study was to determine whether the loss of the transcription factor Mef2c early in B-cell development could alter the phenotype and function of the maturing cells. Mef2c KO is an embryonic lethal KO such that we and other groups have utilized conditional KO approaches for B-cell analysis. When Mef2c is eliminated in the earliest of hematopoietic lineage steps, the development of lymphoid lineages is dramatically reduced while myeloid lineage development is enhanced (11) . The loss of Mef2c in B-cells coincident with Vav expression in the emerging HSCs displays a depressed development of B-cells in the marrow at the pre-pro B cell stage in young mice (4 weeks) and a reduction in the pro-B-cells in animals 9-10 months of age (13) . As reported in this manuscript, using a Mb-1-Cre-mediated deletion of (10, 12) . These data thus suggest that Mef2c functions to regulate the development of B-cells at three separate check points: (i) prior to the diversification of the common lymphoid and myeloid progenitor cells, (ii) at the development of the earliest of committed B-cell lineages and (iii) during the development of more mature, Hardy fractions prior to migration of the immature B-cells into the peripheral lymphatic tissues. We did not analyze mature B-cell functions in this report (previously documented in the Cd19-Cre-mediated inactivation of Mef2c) since both the Cre deletion strains (Cd19 and Mb-1) provide for efficient deletion of the gene in the mature B-cell populations and should thus provide for identical data.
Mef2c belongs to the MADS domain MEF2 family of transcription factors and it has been extensively studied for its role in skeletal muscle formation, bone development and cardiac morphogenesis (4, 6, 7, 17, 45, 46) . Mef2c can function to either activate or repress gene transcription either alone or in close contact with other factors (30) . The specific mechanism by which Mef2c controls B-cell development at the previously described checkpoints is not known but our analysis of gene expression profiling of the Mef2c-deficient marrow B-cells has provided a number of potential Mef2c targets ( Table 2 ) that could be used in rescue assays with Mef2c-deficient bone marrow. A recent study analyzed the role of Erk kinases in pre-BCR signaling to allow for early B-cell expansion (47); animals lacking Erk1 and Erk2 were unable to expand B-cells past the pre-BCR expansion stage. One gene showing altered (depressed) transcription in the Erk1/2 deficient cells was Mef2c; Erk1/2 KO cells could be rescued at this block in differentiation by the forced expression of Mef2c (as well as Myc, Ilf2 or Mef2d). These data suggest that the Mef2c deficient B-cells could also be rescued by the forced expression of one or more of the transcription factors listed in Table 2 .
The two previous reports using the CD19-cre-mediated deletion of Mef2c noted either a complete loss of expression of CD23 on the surface of all mature B-cells or the loss of CD23 on a subset of B-cells. Our analyses indicate that the majority of mature B-cells do retain expression of CD23 but that a subset fails to express the gene even under conditions conducive for CD23 expression. The transcriptional regulation of CD23/ Fcer2a is proposed to be regulated by a number of factors such that one subset of B-cells may allow for expression of CD23/ Fcer2a, in the absence of Mef2c, due to the presence of other compensatory transcriptional control proteins. The complete dissection of the transcriptional control of FcɛR2α during various stages of B-cell development may ultimately require compound knockouts of multiple transcriptional regulators.
Our analyses of altered gene expression in the Mef2c KO B-cells also demonstrated a dramatic reduction of Ciita expression with the loss of expression of many of its target genes. Ciita is constitutively expressed by antigen-presenting cells such as B-cells and dendritic cells, and is also highly induced by IFN-γ through a Stat1/Irf1/Brg1-dependent pathway (48) (49) (50) . The Ciita gene possesses multiple promoters one of which is specific for B-cell expression (51) but the transcription factors that control lymphocyte expression of this gene have not been defined. The role of Mef2c in regulating the constitutive expression of Ciita in B-cells had not been previously noted: the ChIP analysis demonstrating Mef2c-specific binding to the lymphoid Ciita promoter suggests that its regulation is directly dependent upon the function of Mef2c. Deficiency of Ciita leads to the severe immunodeficiency bare lymphocyte syndrome, and is also associated with arthritis, multiple sclerosis and myocardial infarctions (51, 52) .
The elevated transcription of Tfnsf4 (Ox40l) noted in the Mef2c-deficient B-cells could allow for heightened binding of this ligand to the co-stimulatory receptor on T cells potentially leading to their altered activation (33) . The expression of Tfnsf4 (Ox40l) by B-cells has primarily been studied in context of promoter polymorphisms (disease susceptibility polymorphisms in the human TNFNSF4 gene lead to enhanced expression) that are associated with increased risk of myocardial infarctions, atherosclerosis, systemic sclerosis and systemic lupus erythematosus (53) (54) (55) (56) . Intriguingly, the loss of Mef2c leads to depressed levels of expression of Ciita and an enhanced level of expression of Tnfsf4, both of which are linked, in human studies, to autoimmune responses and myocardial damage. Thus depressed Mef2c expression in B-cells may create an underlying susceptibility to these types of syndromes, and the Mef2c KO animal may be an ideal model to screen for heightened susceptibility to these diseases.
We previously demonstrated that Mef2c expression in FM cells is, based on β-actin equivalents, higher than that found in MZ B-cells (9) . In this report we show that the loss of Mef2c results in the depressed expression of CD23 (at least on a subset of mature B-cells) and an elevated level of expression of the Cr1/Cr2 proteins. MZ cells are also notable for their depressed expression of CD23 and elevated expression of the Cr1/Cr2 proteins. Therefore, the differentiation between MZ and FM cells may be due, in part, to the expression levels of Mef2c which control the level of expression of these mature B-cell products. The generation and maintenance of MZ cells also requires Notch signaling (57, 58) and Notch signaling serves to depress Mef2c expression and function (59-61) Therefore one effect of Notch signaling in the development of MZ B-cells may be to suppress CD23/Fcer2a expression and enhance Cr2 gene expression by depressing the synthesis and function of Mef2c.
In summary our study of Mb-1-Cre-mediated B-cell-specific deletion of Mef2c shows its effect on B-cell development by creating a significant reduction of immature B-cells. The effect is fully restored in mature adult Mef2c KO mice. Our data also describe a transcriptional loss of CD23 in a defined Table 2 . Altered expression levels of transcription factors in the Mef2c deficient marrow and spleen B-cells (see Table 1 for details). 
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subset of Mef2c KO B-cells suggesting multiple transcriptional activators serve to facilitate Mef2c expression (20, 62) . The absence of Mef2c protein leads to altered expression of a number of genes encoding key regulatory proteins of the mature B-cell including Ciita, Tnfsf4 (Ox40l), CD23 and the Cr1/Cr2 complement receptor proteins.
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